Turning Point Therapeutics Deal History & Licensing Activity
Turning Point Therapeutics is a large biotech headquartered in US. Over the past three years, Turning Point Therapeutics has been involved in 4 licensing and acquisition transactions, with a primary focus on Mab (2 deals). The company currently has 4 active clinical trials, primarily in Oncology.
Deals (12mo)
1
Active Trials
4
Top Modality
Mab
Focus Area
Oncology
Turning Point Therapeutics Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Turning Point Therapeutics in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| TIM-3-301 | Amgen | Mab | Discovery | collaboration | Dec 2025 |
Turning Point Therapeutics Pipeline Focus
Therapeutic areas and modalities where Turning Point Therapeutics is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Turning Point Therapeutics Strategic Signals
Key indicators of Turning Point Therapeutics's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Turning Point Therapeutics Clinical Pipeline
Turning Point Therapeutics has 4 active clinical trials across 1 development phase.
4
Phase 1
See How Your Asset Matches Turning Point Therapeutics's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Mab Benchmarks
Upfront, milestone, and royalty benchmarks for mab deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Turning Point Therapeutics Licensing & Deal Activity
Turning Point Therapeutics is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 4 deals over the past three years, Turning Point Therapeutics ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Turning Point Therapeutics include Oncology (5 deals and trials), Hematological Malignancies (2 deals and trials), and Solid Tumors (1 deal and trial). In terms of modality, Turning Point Therapeutics has shown particular interest in mab, small molecules, car-t.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Turning Point Therapeutics and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Turning Point Therapeutics's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.